3rd Annual Gene Therapy Analytical Development Europe (description)


Address:239 Vauxhall Bridge Rd, Pimlico London, England, United Kingdom SW1V 1EQ
Event dates:5/30/2022 - 6/1/2022 (This event has already taken place)
Event web site:
findCE GPA: This event is not yet rated. Click here to view a sample report card
Click here to rate 3rd Annual Gene Therapy Analytical Development Europe


Topics to be Covered:

  • Axel Ståhlbom, Current Member, EDQM Gene Therapy Products working party
  • Sol Ruiz, Head of Biologics, Biotechnology, and Advanced Therapies, Spanish Medicines Agency (AEMPS)
  • Luca Biasco, Translational research, AvroBio
  • Science, Health & Medicine
  • Pharmaceuticals
Organizer phone:+4402031418700
Offering type:Conference
Specialty:Data not provided
Event frequency:Never
First Meeting:
Total events:
Est. attendance:
Target audience:Any
Other target audiences:
Host Sponsor:Hanson Wade
Est. # of exhibitors:
Currency:British Pounds
Language:Data not provided
CE Credits:
Organizer URL


In the context of unprecedented gene therapy investment and clinical progress, with mounting regulatory scrutiny, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency, quality, and safety of gene therapy products.

Whether you're looking for specific characterisation, potency or infectivity approaches to improve your current analytical toolbox or if you're seeking to understand how gene therapy analytics differ from other biologics you've worked on in the past, this focused, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors, delivered by 'boots on the ground' scientists grappling with these challenges first-hand.

Join 150+ analytical pioneers to discover the realities of working with tools like dPCR, AUC and HPLC, as well as how and where these tools can be most effective in process development, and what the European regulators expect in order to grant approval. Whether you're working with AAV or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.

Speakers: Axel Ståhlbom, Current Member, EDQM Gene Therapy Products working party, Sol Ruiz, Head of Biologics, Biotechnology, and Advanced Therapies, Spanish Medicines Agency (AEMPS), Luca Biasco, Translational research, AvroBio, Guillaume Cornelis, Senior Scientist, Team Leader, Cellectis, Shyamtanu Datta, Bioassay Expert Gene Therapy Scientist, Roche, Xiaohui Lu, Senior Director, Analytical Development, Ultragenyx, Christine LE BEC, Head of CMC Gene Therapy, Sensorion, James Norton, MSAT Analytical Development Lead, MeiraGTx Gene Therapy Facility, Niamh Kinsella, Global Regulatory CMC Early Development Gene Therapy Lead, Biogen, Simon Briggs, Head of Gene Therapy Technical Product Development, Biogen, Nathalie Uzcátegui, Senior Scientist, Hansa Biopharma, Chaminda Salgado, Vice President of CMC, T-Cypher Bio, Guoxiu Breslau, Senior Scientist, PTC Therapeutics, Tushar Patel, Associate Director, Analytical Development, Vedere Bio, Felix Fuchsberger, Tech Development Scientist, Takeda, Paul Devine, Senior Scientist, AstraZeneca, Bernd Innthaler, Lead Separation Methods, Gene Therapy Process Development, Takeda, Jenifer Kaplan, Principal Scientist I, Novartis, Steven Wolk, Vice President, Analytical Chemistry & Site Head Boulder, Editas, Ernest Milian, CMC Manager, VCN Biosciences, François Gianelli, Senior Director, CMC, Voisin Consulting, Roland Pach, Global Expert CGT Analytics, Roche, Elaine Peters, CMC & Director Analytics iNest, Genentech, Judy Shimoni, Technical Development Lead, Pharma Technical Development Project and Portfolio Management, Genentech, Ilya Shestopalov, Director and Analytical, Product Lead, bluebird bio, Speaker to be confirmed, Sciex, Speaker to be confirmed, Coriolis Pharma, Speaker to be confirmed, Sartorius, Speaker to be confirmed, Bio-Rad, Speaker to be confirmed, Beckman Coulter, Speaker to be confirmed, Unchained Labs, Speaker to be confirmed, Progen, Speaker to be confirmed, Refeyn


Time: 9:00 AM - 5:10 PM

Registration Fee Details:

2 Day Conference + Workshop Day - Standard Pricing GBP 4496.00
2 Day Conference Only - Standard Pricing GBP 3599.00
2 Day Conference + Workshop Day - Drug Developer Pricing GBP 3496.00
2 Day Conference Only - Drug Developer Pricing GBP 2599.00

Other items that tuition includes:

Travel and hotel arrangements:

Contact Person:Emily Birt
Organizer State/Province: (Outside US)
Organizer CountryData not provided
Organizer Phone+4402031418700
Structural makeupData not provided
Host Sponsor; Other SponsorsHanson Wade
Event Site/VenueVictoria Park Plaza Hotel
Event sold out?No
Multiple locations or dates?No
Statistics available for most recent event held in:NA
Average number in event attendance of:
Number in attendance of:
total attendance #: 1000
Target BoundariesInternational
Is Registration contact information the same as Organizer Contact above?Yes
Web Page
Can one register for your CE on your web site?NA
Can registration be made by snail (regular) mail?Yes
Online housing reservations: 
Do you have additional written or AV materials for sale?No
If so, are they available for non-attendees as well as those attending?NA
Is full tuition necessary to ensure registration?No
Will there be shuttle service available?NA
Additional notes:Brochure

Sign In/Sign Out
About Us
Contact Us